

Deotima Chakraborty
Research Assistant
Importance of study of protein-protein interaction in disease mechanism research
Published on: November 20, 2024
This presentation focuses on the importance of Protein-Protein Interactions (PPIs) in the functioning of cells under normal circumstances and also how they are involved in certain diseases, particularly in neurodegenerative diseases and cancer. It shows how the effects of PPIs are pathological processes that are not directly related to the normal function of these components, such as how proteins coalesce into aggregates in the case of Parkinson’s disease and swelling in acute conditions. The analysis of structure-specific interactomes calls attention to the PPI network in the context of the advancement of the disease and response to therapy, which is also the case in the evaluation of treatment efficacy. The presentation addresses the methods such as mass spectrometry and assays based on affinity, which are used to routinely discover and study the interactions of proteins. Systems such as the dysfunctional Protein-Protein Interactome (dfPPI) platform were also discussed as invaluable tools in the study of the temporal variations of PPI dynamic patterns under physiological stress or disease conditions. These techniques allow correlating alterations in PPIs to disease phenotypes at the molecular level. Therapeutic relevance was put at the forefront since PPIs represent an exciting area for drug development. The study explained how the modulation of PPIs can be employed to restore disrupted networks and improve the effectiveness of drugs in the treatment of neurodegenerative disorders and cancers. Conclusion The paper in the presentation recommends the use of Artificial Intelligence in the design of PPI modulators and the use of high-throughput profiling of complexes for understanding plant PPI networks in live cells. It is hoped that this will help overcome the present difficulties in the PPI datasets complexities and assist in coming up with new ways of developing therapeutics.
